• Explore /
  • Poster
  • / GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

Abstract Poster

Authors

null

Ciara Conduit

Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, Australia

Ciara Conduit , Blossom Mak , Wenjia Qu , Theresa Yeung , Mathias Bressel , Thomas Cusick , Haryana M. Dhillon , Richard De Abreu Lourenço , Craig Underhill , Javier Torres , Megan Crumbaker , Florian Honeyball , Anthony Linton , Sanjeev Sewak , Nguyen Minh Hieu Chau , Ray Allen , Ian D. Davis , Susan J. Clark , Lisa Horvath , Kate Lynette Mahon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Clinical Trial Registration Number

NCT04918810

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5099)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5099

Abstract #

TPS5099

Poster Bd #

192b

Abstract Disclosures

Similar Posters

First Author: Shahneen Kaur Sandhu

First Author: Carlo Buonerba

First Author: Elisabeth I. Heath

First Author: S. M. Seng